The same frameshift mutation in PALB2 has been reported for a patient with Fanconi anemia (Reid et al., 2007), and talazoparib has subsequently been shown to be active for patients with germline PALB2 mutations (Gruber et al., 2022). Here, PALB2 is linked to Fanconi anemia.